Lenacapavir trials proved the science works. But experts say the real test is if health systems, governments, and donors can deliver.
The promise of lenacapavir crackled through the halls in Kigali: two injections a year, near-total protection, and overwhelming demand from those too often left out of prevention trials. For a moment, it felt like history bending toward possibility. But outside the euphoria lies the harder question — whether health systems, governments, and Big Pharma can move fast enough to turn a scientific breakthrough into protection in the real world.
“With injectables, you re-medicalize prevention,” said professor Glenda Gray, director of the Infectious Disease and Oncology Research Institute at the University of the Witwatersrand. “You need a nurse, HIV testing, diagnostics at the point of delivery, and a supply chain that never fails. That is not simple.”
Read the full story at Devex /free registration is required/.
Source : Devex
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.